Compare AIP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | STRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 767.5M | 338.9M |
| IPO Year | 2021 | N/A |
| Metric | AIP | STRO |
|---|---|---|
| Price | $16.52 | $24.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $16.83 | ★ $26.38 |
| AVG Volume (30 Days) | ★ 420.9K | 167.1K |
| Earning Date | 05-12-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,579,000.00 | N/A |
| Revenue This Year | $30.24 | N/A |
| Revenue Next Year | $19.50 | $13.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $5.64 | $0.52 |
| 52 Week High | $19.85 | $27.96 |
| Indicator | AIP | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 63.91 |
| Support Level | $15.10 | $0.76 |
| Resistance Level | $18.00 | $27.96 |
| Average True Range (ATR) | 0.92 | 2.27 |
| MACD | 0.21 | -0.12 |
| Stochastic Oscillator | 46.19 | 63.15 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.